Revised Airlie House ALS Clinical Trial Guidelines

In March 2016, Senda Ajroud-Driss, MD, Director of the Lois Insolia ALS Clinic, Associate Professor of Neurology and Teepu Siddique, MD, Les Turner ALS Foundation/Herbert C. Wenske Professor, Professor of Neurology and Cell and Molecular Biology, were two of 140 key members of the international ALS community to draft the Revised Airlie House ALS Clinical Trial Guidelines. Today, Neurology published the revised guidelines that are more expansive in their representation of ALS and understand the urgency for people living with ALS.

Dr. Senda Ajroud-Driss

“Over the last 20 years, ALS research has rapidly evolved. It was critical to update the guidelines to include the patient voice and to represent the full spectrum of how ALS presents in different people. We also wanted to build on the lessons learned from previous ALS clinical trials,” explains Dr. Ajroud-Driss about the importance to update the guidelines.

Dr. Ajroud-Driss continues, “There is an urgent need for people living with ALS to have access to investigational therapies and treatments and we believe these revised guidelines will help ALS researchers accelerate the development of effective treatments.

Our Les Turner ALS Center at Northwestern Medicine has contributed to groundbreaking discoveries in ALS and, with these revisions, we hope to bring more clinical trials to Chicago to move rapidly towards a cure.”

We are very grateful to all those who spent the considerable time and effort to improve these guidelines, under the leadership of Hiroshi Mitsumoto, MD, DSc of Columbia University.

View the Revised Airlie House ALS Clinical Trial Guidelines here.